Ongoing investigations are evaluating the efficacy and safety profiles of these novel receptor agonist combinations, although clinical data remain unavailable in the near future
GLP-1s also slow digestion and make you feel full longer
In addition, combining semaglutide with cilofexor, a farnesoid X receptor agonist, and/or firsocostat, an acetyl-CoA carboxylase inhibitor, has also shown potential in preclinical studies
Therefore, considering the widespread use of these medications, it is crucial to elucidate the potential role of GLP-1RA use in the development of thyroid cancer
However, when combined with insulin or sulfonylureas, the risk of low blood sugar increases significantly, requiring careful monitoring and possible dose adjustments of those medications
That status changed in December 2025 with the FDA approval of an oral version of Wegovy (also manufactured by Novo Nordisk)